Insmed Q1 2020 Earnings Report

Insmed reported financial results for the first quarter ended March 31, 2020, and provided a business update.

Key Takeaways

Insmed reported their Q1 2020 financial results, highlighting their support for the NTM lung disease community and uninterrupted supply of ARIKAYCE amidst the COVID-19 pandemic. They had cash and cash equivalents of $428.9 million as of March 31, 2020, and total operating expenses for the first quarter of 2020 were $88.8 million.

Supported an investigator-initiated study of brensocatib in patients with severe COVID-19.

Supported the NTM lung disease community remotely and provided an uninterrupted supply of ARIKAYCE.

Submitted a new drug application to the Ministry of Health, Labour and Welfare in Japan for ARIKAYCE for the treatment of patients with NTM lung disease caused by MAC.

Plans to file an Investigational New Drug application and initiate a Phase 1 study of treprostinil palmitil in the second half of 2020.

Total Revenue

$36.9M

Previous year: $21.9M

+68.3%

EPS

-$0.74

Previous year: -$0.96

-22.9%

Cash and Equivalents

$429M